Asthma
GSK’s Nucala Demonstrates Efficacy in COPD with Positive Phase III Trial Results
GSK, Nucala, COPD, Phase III trial, mepolizumab, chronic obstructive pulmonary disease, asthma, IL-5 antagonist, monoclonal antibody.
RAPT Therapeutics Announces Significant Workforce Reduction Following Clinical Hold on Zelnecirnon Trials
RAPT Therapeutics, zelnecirnon, clinical hold, workforce reduction, FDA, clinical trials, atopic dermatitis, asthma, oncology, CCR4 agonist
GSK’s RSV Vaccine Wins Expected Expansion into At-Risk Adults Aged 50-59
GSK, RSV vaccine, Arexvy, FDA approval, adults aged 50-59, increased risk, respiratory syncytial virus, lower respiratory tract disease, medical conditions, chronic obstructive pulmonary disease, asthma, heart failure, diabetes.
GSK’s Novel Long-Acting Asthma Treatment Shows Promising Results in Phase 3 Trials
GSK, asthma treatment, Phase 3 studies, long-acting, clinical trials, efficacy, safety, respiratory disease
Sanofi Eyes COPD Treatment as Major Growth Driver for Dupixent, Says CEO
Sanofi, Dupixent, COPD, growth pillar, immunology, CEO, treatment, expansion, clinical trials, asthma, atopic dermatitis.
Boehringer Ingelheim Caps Out-of-Pocket Costs for Asthma and COPD Inhalers in the U.S.
Boehringer Ingelheim, Out-of-pocket costs, Asthma, COPD, Inhalers, $35 cap, June 1/ 2024, Uninsured and under-insured patients, List price reduction